{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:30Z","timestamp":1792784610273,"version":"4.5.0"},"reference-count":58,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"National Natural Science Foundation of China","award":["21572271"],"award-info":[{"award-number":["21572271"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangzhou National Laboratory","award":["SRPG22-002"],"award-info":[{"award-number":["SRPG22-002"]}],"id":[{"id":"https:\/\/ror.org\/03ybmxt82","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic hepatitis C virus (HCV) infection remains a critical global public health burden affecting hundreds of millions of people worldwide. The emergence of antiviral resistance persistently undermines the long-term clinical efficacy of current direct-acting antiviral (DAA) regimens, creating an urgent need for therapeutics with different mechanisms of action. Host-directed multi-target therapy offers a promising avenue to overcome DAA resistance, yet dual inhibitors targeting HCV-essential host kinase phosphatidylinositol 4-kinase III\u03b2 (PI4KIII\u03b2) and epigenetic regulator histone deacetylases (HDACs) have not been reported for HCV treatment to date. Herein, we describe the rational design, chemical synthesis, and comprehensive biological evaluation of a series of novel thiazolamide-based dual PI4KIII\u03b2\/HDAC inhibitors. Lead compounds displayed potent dual-target enzymatic inhibition, robust in vitro anti-HCV activity and excellent in vivo tolerability. This work establishes a novel host-directed dual-target therapeutic paradigm for HCV, providing a viable strategy to address the unmet clinical challenge of DAA resistance.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01344","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T07:03:06Z","timestamp":1791788586000},"page":"23770-23789","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of Thiazolamide-based PI4KIII\u03b2\/HDAC Dual Inhibitors with Potent Activity against Hepatitis C Virus"],"prefix":"10.1021","volume":"69","author":[{"given":"Enyuan","family":"Wang","sequence":"first","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xue","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuolei","family":"Jia","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichao","family":"Chen","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Gao","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglan","family":"Hu","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Han","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqin","family":"Ruan","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Guo","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6360-2285","authenticated-orcid":true,"given":"Qingfa","family":"Zhou","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"1","key":"2026102305084886900_cit1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J. Hepatol."},{"issue":"2","key":"2026102305084886900_cit2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"26","key":"2026102305084886900_cit3","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.4254\/wjh.v7.i26.2676","article-title":"Hepatitis C virus: A global view","volume":"7","author":"Mohamed","year":"2015","journal-title":"World J. Hepatol."},{"issue":"2","key":"2026102305084886900_cit4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14218\/jcth.2017.00067","article-title":"Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review","volume":"6","author":"Axley","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"4","key":"2026102305084886900_cit5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.apsb.2014.06.002","article-title":"Synthesis and biological evaluation of sophocarpinic acid derivatives as anti-HCV agents","volume":"4","author":"Li","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"2026102305084886900_cit6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1021\/acs.jmedchem.3c01971","article-title":"Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3\/4A Peptidomimetic Inhibitors. What Did We Learn?","volume":"67","author":"Martino","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026102305084886900_cit7","doi-asserted-by":"publisher","first-page":"7457","DOI":"10.1038\/s41467-023-42550-6","article-title":"Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"issue":"7","key":"2026102305084886900_cit8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nm.3183","article-title":"Current progress in development of hepatitis C virus vaccines","volume":"19","author":"Liang","year":"2013","journal-title":"Nat. Med."},{"issue":"5","key":"2026102305084886900_cit9","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1021\/acs.jmedchem.3c01543","article-title":"Antiviral Protein-Protein Interaction Inhibitors","volume":"67","author":"Markovic\u0301","year":"2024","journal-title":"J. Med. Chem."},{"issue":"22","key":"2026102305084886900_cit10","doi-asserted-by":"publisher","first-page":"13197","DOI":"10.1021\/acs.jmedchem.0c01877","article-title":"The 2020 Nobel Prize in Physiology or Medicine","volume":"63","author":"Meanwell","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026102305084886900_cit11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.apsb.2015.09.008","article-title":"Direct anti-HCV agents","volume":"6","author":"Zhang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"2026102305084886900_cit12","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1128\/aac.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026102305084886900_cit13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/nyas.12832","article-title":"Development of sofosbuvir for the treatment of hepatitis C virus infection","volume":"1358","author":"Lawitz","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"2026102305084886900_cit14","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1021\/jm401507s","article-title":"Discovery and development of simeprevir (TMC435), a HCV NS3\/4A protease inhibitor","volume":"57","author":"Rosenquist","year":"2014","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026102305084886900_cit15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14218\/jcth.2020.00031","article-title":"Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis","volume":"8","author":"Rao","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"6","key":"2026102305084886900_cit16","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1021\/acs.jmedchem.4c00090","article-title":"Design, Synthesis, and Structure-Activity Relationship of Novel Pyridazinone-Based PARP7\/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition","volume":"67","author":"Duan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026102305084886900_cit17","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1021\/acs.jmedchem.0c00193","article-title":"Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K\/HDAC Inhibitors","volume":"63","author":"Thakur","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026102305084886900_cit18","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1021\/acs.jmedchem.3c01941","article-title":"Multitargeting HDAC Inhibitors Containing a RAS\/RAF Protein Interfering Unit","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026102305084886900_cit19","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1021\/acs.jmedchem.4c01859","article-title":"Indolo[3,2-c]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026102305084886900_cit20","doi-asserted-by":"publisher","first-page":"11062","DOI":"10.1021\/acs.jmedchem.5c00040","article-title":"Rational Design of Novel Quinazolinone-Pyrrolodihydropyrrolone Analogs as PIM\/HDAC Dual-Target Inhibitors for the Treatment of Acute Myelocytic Leukemia","volume":"68","author":"Xin","year":"2025","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026102305084886900_cit21","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1021\/acs.jmedchem.4c03084","article-title":"Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3\/VEGFR2\/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia","volume":"68","author":"Tian","year":"2025","journal-title":"J. Med. Chem."},{"issue":"21","key":"2026102305084886900_cit22","doi-asserted-by":"publisher","first-page":"19267","DOI":"10.1021\/acs.jmedchem.4c01681","article-title":"Discovery of Janus Kinase and Histone Deacetylase Dual Inhibitors as a New Strategy to Treat Psoriasis","volume":"67","author":"Hu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"18","key":"2026102305084886900_cit23","doi-asserted-by":"publisher","first-page":"16480","DOI":"10.1021\/acs.jmedchem.4c01310","article-title":"Development of a First-in-Class DNMT1\/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity","volume":"67","author":"Chang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026102305084886900_cit24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41573-022-00582-5","article-title":"Beyond PI3Ks: targeting phosphoinositide kinases in disease","volume":"22","author":"Burke","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026102305084886900_cit25","doi-asserted-by":"publisher","first-page":"102207","DOI":"10.1016\/j.ceb.2023.102207","article-title":"PI4KA and PIKfyve: Essential phosphoinositide signaling enzymes involved in myriad human diseases","volume":"83","author":"Barlow-Busch","year":"2023","journal-title":"Curr. Opin. Cell Biol."},{"issue":"3","key":"2026102305084886900_cit26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/tra.12841","article-title":"Molecular mechanisms of PI4K regulation and their involvement in viral replication","volume":"24","author":"McPhail","year":"2023","journal-title":"Traffic"},{"issue":"527","key":"2026102305084886900_cit27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax3772","article-title":"PI4KIII\u03b2 is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma","volume":"12","author":"Tan","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"2026102305084886900_cit28","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.1021\/acs.jmedchem.4c02588","article-title":"Discovery of 5-Phenylthiazol-2-amine Derivatives as Novel PI4KIII\u03b2 Inhibitors with Efficacious Antitumor Activity by Inhibiting the PI3K\/AKT Axis","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026102305084886900_cit29","doi-asserted-by":"publisher","first-page":"112012","DOI":"10.1016\/j.ejmech.2019.112012","article-title":"Discovery of 6\u2019-chloro-N-methyl-5\u2019-(phenylsulfonamido)-[3,3\u2019-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium","volume":"188","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"2026102305084886900_cit30","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1021\/acs.jmedchem.4c01154","article-title":"2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors of Plasmodium falciparum Phosphatidylinositol-4-kinase and Hemozoin Formation with In Vivo Efficacy","volume":"67","author":"Dziwornu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"18","key":"2026102305084886900_cit31","doi-asserted-by":"publisher","first-page":"8061","DOI":"10.1021\/acs.jmedchem.8b00329","article-title":"Plasmodial Kinase Inhibitors: License to Cure?","volume":"61","author":"Cabrera","year":"2018","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026102305084886900_cit32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1021\/acs.jmedchem.6b01465","article-title":"Rational Design of Novel Highly Potent and Selective Phosphatidylinositol 4-Kinase III\u03b2 (PI4KB) Inhibitors as Broad-Spectrum Antiviral Agents and Tools for Chemical Biology","volume":"60","author":"Mejdrova\u0301","year":"2017","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026102305084886900_cit33","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1021\/acs.jmedchem.8b00648","article-title":"Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria","volume":"61","author":"Kandepedu","year":"2018","journal-title":"J. Med. Chem."},{"issue":"46","key":"2026102305084886900_cit34","doi-asserted-by":"publisher","first-page":"16617","DOI":"10.1002\/anie.201907632","article-title":"Discovery of the Hedgehog Pathway Inhibitor Pipinib that Targets PI4KIII\u00df","volume":"58","author":"Kremer","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"issue":"5","key":"2026102305084886900_cit35","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1021\/acs.jmedchem.5b01311","article-title":"Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase III\u03b2","volume":"59","author":"Rutaganira","year":"2016","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026102305084886900_cit36","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1021\/acs.jmedchem.5b00499","article-title":"Highly Selective Phosphatidylinositol 4-Kinase III\u03b2 Inhibitors and Structural Insight into Their Mode of Action","volume":"58","author":"Mejdrova\u0301","year":"2015","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026102305084886900_cit37","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1128\/aac.01175-13","article-title":"A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase III\u03b2","volume":"57","author":"van der Schaar","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"15","key":"2026102305084886900_cit38","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1021\/acs.jmedchem.8b00521","article-title":"Discovery of a Potent, Orally Bioavailable PI4KIII\u03b2 Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo","volume":"61","author":"Reuberson","year":"2018","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026102305084886900_cit39","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.1021\/acs.jmedchem.3c00036","article-title":"Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers","volume":"66","author":"Qiu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026102305084886900_cit40","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"2026102305084886900_cit41","doi-asserted-by":"publisher","first-page":"116315","DOI":"10.1016\/j.ejmech.2024.116315","article-title":"Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer","volume":"269","author":"Jiang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"2026102305084886900_cit42","doi-asserted-by":"publisher","first-page":"11672","DOI":"10.1021\/acs.jmedchem.3c01160","article-title":"Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms","volume":"66","author":"Mukherjee","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1\u22122","key":"2026102305084886900_cit43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s13148-010-0003-5","article-title":"Histone deacetylases in viral infections","volume":"1","author":"Herbein","year":"2010","journal-title":"Clin. Epigenet."},{"key":"2026102305084886900_cit44","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ijid.2018.04.4242","article-title":"Antiviral with HDAC inhibitor: A Combined Approach Targeting Hepatocellular Carcinoma by HCV","volume":"73","author":"Sahoo","year":"2018","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"2026102305084886900_cit45","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.2337\/db15-0197","article-title":"The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection","volume":"64","author":"Chen","year":"2015","journal-title":"Diabetes"},{"issue":"5","key":"2026102305084886900_cit46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/gene.2013.24","article-title":"Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy","volume":"14","author":"Lo\u0301pez-Rodri\u0301guez","year":"2013","journal-title":"Genes Immun."},{"key":"2026102305084886900_cit47","doi-asserted-by":"publisher","first-page":"111723","DOI":"10.1016\/j.ejmech.2019.111723","article-title":"Structural isomers of cinnamic hydroxamic acids block HCV replication via different mechanisms","volume":"183","author":"Kozlov","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"2026102305084886900_cit48","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"issue":"12","key":"2026102305084886900_cit49","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.1021\/acs.jmedchem.3c00226","article-title":"The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs","volume":"66","author":"Geurs","year":"2023","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026102305084886900_cit50","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"issue":"15","key":"2026102305084886900_cit51","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1021\/acs.jmedchem.8b00050","article-title":"Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4","volume":"61","author":"Lamaa","year":"2018","journal-title":"J. Med. Chem."},{"issue":"16","key":"2026102305084886900_cit52","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1016\/j.bmcl.2019.06.006","article-title":"Synthesis of N\u2019-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV)","volume":"29","author":"Kozlov","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"2026102305084886900_cit53","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1021\/jm501330g","article-title":"Hydroxamic acids block replication of hepatitis C virus","volume":"58","author":"Ai","year":"2015","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026102305084886900_cit54","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12250-018-0057-7","article-title":"Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression","volume":"33","author":"Zhou","year":"2018","journal-title":"Virol. Sin."},{"issue":"8","key":"2026102305084886900_cit55","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.821","article-title":"STAT3 signaling pathway plays importantly genetic and functional roles in HCV infection","volume":"7","author":"Song","year":"2019","journal-title":"Mol. Genet. Genomic Med."},{"issue":"16","key":"2026102305084886900_cit56","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1021\/jm060522a","article-title":"Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring","volume":"49","author":"Lyne","year":"2006","journal-title":"J. Med. Chem."},{"issue":"21","key":"2026102305084886900_cit57","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026102305084886900_cit58","doi-asserted-by":"publisher","first-page":"11017","DOI":"10.3390\/ijms241311017","article-title":"EGCG, GCG, TFDG, or TSA Inhibiting Melanin Synthesis by Downregulating MC1R Expression","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01344","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/23770\/68814894\/jm6c01344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/23770\/68814894\/jm6c01344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:30:16Z","timestamp":1792747816000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/23770\/5448710\/Discovery-of-Thiazolamide-based-PI4KIII-HDAC-Dual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":58,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,10,12]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01344","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}